Oruka Therapeutics, Inc. ORKA R2KR3KPHARMA
Company Overview
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.23.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +422.83% |
| 6 Months: | +16.11% |
| 3 Months: | -11.14% |
| 1 Month: | -6.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)45.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 29.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORKA Oruka Therapeutics, Inc. R2KR3KPHARMA | 80.15 | -39.29 | $5.31B | 0.00% | -25.79% | -18.23% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | - | - | - | - |
| Operating Income | -2.82M | -3.67M | -3.94M | -4.71M | -4.38M | -5.56M | -4.47M | - | -2.77M | -2.16M | -1.66M | - | -1.78M | -1.51M | -1.25M | - | -1.34M | -1.31M | -1.99M | - | -4.10M | -4.84M | -4.72M | - | -3.28M | -3.22M | -2.55M | - | -1.80M | -1.97M | -1.94M | - | -2.48M | -21.49M | -29.45M | -25.09M | -28.43M | -34.10M | -36.43M | -50.11M |
| Net Income | -2.81M | -3.65M | -3.89M | -4.66M | -4.34M | -5.52M | -4.43M | -4.20M | -2.73M | -2.12M | -1.59M | -1.49M | -1.66M | -1.44M | -1.16M | -1.23M | -1.32M | -1.30M | -1.99M | -5.12M | -4.10M | -4.83M | -4.71M | -5.68M | -3.27M | -3.15M | -2.33M | -1.17M | -1.35M | -1.48M | -1.42M | -1.09M | -2.01M | -22.24M | -28.62M | -21.00M | -24.57M | -30.28M | -31.82M | -41.21M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.34 | -0.33 | - | -0.23 | -0.22 | -0.16 | - | -0.09 | -0.10 | -0.10 | - | -0.14 | -6.96 | -1.46 | -0.40 | -0.46 | - | - | - |
| R&D Expense | 1.72M | 2.59M | 2.91M | 3.72M | 3.25M | 4.51M | 3.49M | - | 1.72M | 1.15M | 740.00K | - | 662.00K | 440.00K | 347.00K | - | 365.00K | 372.00K | 1.05M | - | 2.88M | 3.58M | 3.44M | - | 2.18M | 1.49M | 1.02M | - | 390.00K | 254.00K | 322.00K | - | 165.00K | 18.67M | 25.69M | 19.93M | 24.09M | 28.99M | 29.14M | 43.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Operating Income | - | - | - | - | - | - | -9.18M | -7.36M | -4.32M | -6.94M | -9.69M | -11.46M | -16.61M | -18.71M | -8.12M | -5.81M | -9.77M | -19.34M | -10.60M | -7.30M | -88.12M | -122.05M |
| Net Income | -511.00K | -1.46M | -5.24M | -13.99M | -19.43M | -9.14M | -8.42M | -5.36M | -4.32M | -6.94M | -9.69M | -11.45M | -16.44M | -18.49M | -7.93M | -5.48M | -9.74M | -19.32M | -9.93M | -5.34M | -83.72M | -105.43M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.39 | -0.69 | -0.37 | -3.87 | - |
| R&D Expense | - | - | - | - | - | - | 3.11M | 2.31M | 1.09M | 2.93M | 5.62M | 7.06M | 12.35M | 14.08M | 4.24M | 1.83M | 4.99M | 13.83M | 4.75M | 1.01M | 75.06M | 100.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Feb 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | 8.16M | 6.50M | 3.21M | 17.08M | 16.13M | 39.57M | 24.63M | 12.37M | 6.83M | 8.54M | 50.43M | 54.92M | 43.09M | 37.86M | 1.00K | 396.02M | 488.62M |
| Total Equity | -115.00K | -619.00K | -678.00K | -5.74M | -19.69M | -38.18M | 7.41M | 6.77M | 5.73M | 2.91M | 15.58M | 14.74M | 38.07M | 22.19M | 10.28M | 6.03M | 7.61M | 46.52M | 51.04M | 41.67M | 37.02M | 1.00K | 382.22M | 471.93M |
| Cash & Equivalents | - | - | - | - | - | - | 7.76M | 7.03M | 5.94M | 2.92M | 16.76M | 15.35M | 38.80M | 7.40M | 8.70M | 6.61M | 8.36M | 49.07M | 53.36M | 42.45M | 37.43M | - | 61.58M | 46.94M |
| Total Liabilities | - | - | - | - | - | - | - | 1.39M | 770.00K | 305.00K | 1.50M | 1.39M | 1.50M | 2.44M | 2.09M | 793.00K | 926.00K | 3.91M | 3.88M | 1.41M | 841.00K | - | 13.80M | 16.69M |
| Current Liabilities | - | - | - | - | - | - | - | 1.19M | 754.00K | 305.00K | 1.50M | 1.39M | 1.50M | 2.40M | 2.07M | 793.00K | 926.00K | 3.50M | 3.50M | 1.13M | 637.00K | - | 13.04M | 15.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.32M | -6.96M | -4.08M | -5.29M | - | - | - | -17.47M | -8.24M | -4.80M | -7.72M | -18.76M | -10.91M | -5.01M | -57.84M | -88.21M |
| Investing Cash Flow | 265.00K | 2.01M | - | -32.00K | - | - | - | 12.93M | 3.05M | -4.00K | -19.00K | -43.00K | -2.00K | 0 | -330.13M | -96.75M |
| Financing Cash Flow | 7.32M | 3.87M | 1.05M | 19.16M | - | - | - | 5.85M | 3.10M | 6.56M | 48.45M | 23.09M | 0 | 0 | 449.54M | 170.31M |
| Capital Expenditure | -4.00K | -19.00K | - | -32.00K | -19.00K | -11.00K | -12.00K | -3.00K | -4.00K | -4.00K | -19.00K | -43.00K | -2.00K | -0 | -189.00K | -209.00K |
| Free Cash Flow | -8.33M | -6.98M | - | -5.32M | - | - | - | -17.48M | -8.25M | -4.80M | -7.74M | -18.80M | -10.91M | -5.01M | -58.03M | -88.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 82.6% | 215.2% | 91.2% | 71.1% | 50.9% | -123.3% | -124.4% | -93.6% | -148.6% | -44.5% | -65.7% | -30.1% | -74.1% | -180.0% | -131.5% | -72.0% | -20.9% | -37.9% | -23.8% | -14.4% | -21.9% | -22.3% |
| ROCE % | - | - | - | - | - | - | -131.7% | -128.1% | -148.6% | -44.5% | -65.7% | -30.1% | -74.7% | -181.8% | -134.6% | -76.4% | -20.8% | -37.6% | -25.3% | -19.6% | -23.0% | -25.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 13.68% | 9.06M | $743.72M |
| 2 | Blackrock Inc. | 7.54% | 4.99M | $409.74M |
| 3 | Venrock Adviser, LLC | 6.27% | 4.15M | $340.63M |
| 4 | Fairmount Funds Management LLC | 5.60% | 3.71M | $304.24M |
| 5 | Capital World Investors | 5.14% | 3.40M | $279.31M |
| 6 | RTW Investments LP | 4.74% | 3.14M | $257.75M |
| 7 | State Street Corporation | 4.04% | 2.67M | $219.49M |
| 8 | Vanguard Capital Management LLC | 3.57% | 2.36M | $193.86M |
| 9 | Paradigm Biocapital Advisors LP | 3.24% | 2.14M | $176.09M |
| 10 | Deep Track Capital, Lp | 2.91% | 1.93M | $158.14M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ORKA
Oruka Therapeutics (ORKA) Stock May Be Trading On A Rich Premium To Book Value - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQQ3pfU3lnZFBnT3ZBTERDaWNfNjhJRG1ocmM4U2lTYm8tcjYyWFh5ZEVidkRkTWZENTYteXg4ZUJnRU5aUHF5ZDFUc01xMXR1a1p3d1VRZkdQU0MyY1djaHNoTEs2ME1WeFpXWWpZdjhtcjRoWGVacVVXNVFFRG8yYU1zUjhHSUVxZzk2Nn…
ORKA 261120 20.00C (ORKA261120C20000) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBXSnlDV0NnRGpHREVTWktHelEzVUkyLUNQLWpxTzE0SDFoV3FtTGdsLU9MZ1VfbFhXVElTYWw5Ty1RLTJuSGpUVmtETjlfS2lyXzlZWkthUnVIVk1xLUM0?oc=5" target="_blank">ORKA 261120 20.00C (ORKA261120C20000) S…
Oruka Therapeutics: The Psoriasis Market Becoming A Barbell, And ORKA-001 Owns The Far End - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOUE1WZy13ZVo3Y0laS1dlS1NfYU85cXF5c2Jxb3RTRkhKSUlaTVR2NjhwUFU0YjQtNUw5STNOZ1Vpa3pOLWhnSjloOGZWaGxYNlVpWnNLdElOa3NsakFWQ2ZaMTVWdGltWGtGMzNPVlByaUF6aWFSXzMxc3FZbERYWVJhX2tCMWppb3pLMW…
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQZ0UxQWFKejFuMWVwYUZqb082RWc3OHh6VEdPR2VsMTdjSm5xeURhbFg0bTd2THZiT0J1WHczdThaeU8yTlpYeFAxRGRfU09heDBLVDlwT0JsTnBmd1I0eXRQV3hiQlNFVDFPdlp1OU9ENjlIUEpZcENvdVFTZXdKcFRPaFZFWlUtYmNUVk…
Oruka Therapeutics general counsel sells $706k in shares By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNaHhxb1pzdmZfN1dNa2dtM2JTTlpGOUZQQnVnMTFGTk1nZ0tYRF9odm5rQ2JyNTBmMV9LcE5UUDltbzdsUmRJZWdReVFNbFh3OXYtUzZTSUVab2RJOGFCWGdWdjYxd0RVR3AyeUszVnpWYzJTWkxEYksycWF3bDFVXzBIdExnZTVDN0NrWW…
BTIG reiterates Buy rating on Oruka Therapeutics, $151 price target - TradingView
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNSEN1MWVDa0labjl5NnlDRmJnaVJRNEk1LWVLeXU1cTUwbUd2TWFodU1ZX00zVFlMQW5GemNhTUtwQXRUODkxMFRrbnNyaWRSN2YzSV9tLUF2UHNyQ3F5Z2lsZGt4eS1FV2xrUnJ3RkFHQXR0NWpNM0pZRWNxNTl4bExNWTNQTktoNTB0a1…
ORKA — Frequently Asked Questions
What is the current share price of Oruka Therapeutics, Inc. (ORKA)?
As of 2026-10-23 16:27 PDT, Oruka Therapeutics, Inc. (ORKA) trades at $80.15 on NasdaqGM. Its 52-week range is $14.40 to $113.08.
What is the market capitalisation of ORKA?
Oruka Therapeutics, Inc. (ORKA) has a market capitalisation of $5.31B on NasdaqGM.
What is the P/E ratio of ORKA?
ORKA trades at a trailing price-to-earnings (P/E) ratio of -39.29. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 5.22.
What is the return on equity (ROE) of ORKA?
ORKA has a return on equity (ROE) of -18.23%. Its return on capital employed (ROCE) is -25.79%.
Is ORKA a good stock to buy?
This page provides a data-driven analysis of Oruka Therapeutics, Inc. (ORKA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.